Terkko Navigator / -/ Feeds / " ( ( Eturauhanen )|( Prostata )|( Prostata )|( Glandula prostatica )|( Gl. prostatica )|( "

Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk

The evolving clinical use of prostate cancer biomarkers

Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics

MTA1: a vital modulator in prostate cancer

Gene Expression Analysis Reveals Prognostic Biomarkers of the Tyrosine Metabolism Reprogramming Pathway for Prostate Cancer

FOXP2 confers oncogenic effects in prostate cancer through activating MET signalling

Clinical Efficacy and Psychological Impact of Omaha-Based Continuing Care for Prostate Cancer Patients

LMX1B Activated Circular RNA GFRA1 Modulates the Tumorigenic Properties and Immune Escape of Prostate Cancer

Cells, Vol. 11, Pages 2118: Elevated NF-κB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer

Cells, Vol. 11, Pages 2118: Elevated NF-κB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer

Modulating Tumour Hypoxia in Prostate Cancer Through Exercise: The Impact of Redox Signalling on Radiosensitivity

LMX1B Activated Circular RNA GFRA1 Modulates the Tumorigenic Properties and Immune Escape of Prostate Cancer

Biomedicines, Vol. 10, Pages 882: 68Ga-PSMA-11 PET/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma

GreenLight photovaporization of the prostate in high-medical-risk patients: an analysis of the Global GreenLight Group (GGG) database

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy

Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland Analysis

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Prostate Cancer–specific Survival After Radical Prostatectomy Is Improved Among Metformin Users but Not Among Other Antidiabetic Drug Users

Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy

Prostate cancer risk prediction using a polygenic risk score

Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain

Prostate specific antigen for early detection of prostate cancer: longitudinal study.

Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease.

Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease.

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.

Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial.

Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial.

Prostate-cancer mortality at 11 years of follow-up.

Prostate-cancer mortality at 11 years of follow-up.

Prostate-cancer mortality at 11 years of follow-up.

HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).

HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.